Publications
Search our bibliography using the filters on the right-hand side.
Displaying 51 through 100 of 120 publications.
Skip to main content
Proctor C, McBride D, Balp M-M, McLeod L, Hunter S, Tian H, Khalil S, Hollis K, Maurer M. Comparison of twice-daily and once-daily Urticaria Activity Score: results from the first international burden of illness ASSURE-CSU study in inadequately-controlled chronic spontaneous (idiopathic) urticaria. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.
Nabhan C, Zhou X, Day BM, Dawson K, Zelenetz AD, Friedberg JW, Cerhan JR, Link BK, Flowers CR. Disease, treatment, and outcome differences between men and women with follicular lymphoma in the United States. Am J Hematol. 2016 Aug;91(8):770-5. doi: 10.1002/ajh.24401
Maurer M, Houghton K, Stull D, McBride D, Janssens N, Heinrichs N, Antonova E, Balp MM, Khalil S. Characterization of responders to omalizumab: exploratory analysis of phase III data from patients with chronic spontaneous urticaria. Poster presented at the European Academy of Allergy and Clinical Immunology Congress; June 13, 2016. Vienna, Austria.
Muser E, Benson C, Chirila C, Graham J, Woodruff K. Resource use and cost in a randomized, non-inferiority trial of paliperidone palmitate 3 versus 1-month formulations in patients with schizophrenia. Poster presented at the 2016 American Psychiatric Association Annual Meeting; May 14, 2016. Atlanta, GA.
Odom D, Mladsi DM, Purser M, Kaye JA, Palaka E, Charter A, Jensen JA, Sellami D. A matching adjusted indirect comparison of sonidegib and vismodegib in advanced basal cell carcinoma. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A122.
Guminski A, Stull D, Houghton K, Gutzmer R, Migden MR, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Sellami D, Lear J, Dummer R. Change in fatigue and correlations with clinical outcome in patients with advanced basal cell carcinoma treated with sonidegib in the BOLT study. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A159.
Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Zhou X, Taylor M, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR. Outcomes following watchful waiting for stage II–IV follicular lymphoma patients in the modern era. Br J Haematol. 2016 Mar;172(5):724-34. doi: 10.1111/bjh.13895
Stull DE, McBride D, Houghton K, Finlay AY, Gnanasakthy A, Balp MM. Assessing changes in chronic spontaneous/idiopathic urticaria: comparisons of patient-reported outcomes using latent growth modeling. Adv Ther. 2016 Feb;33(2):214-24. doi: 10.1007/s12325-016-0282-0
Hess LM, Rajan N, Winfree K, Davey P, Ball M, Knox H, Graham C. Cost analyses in the US and Japan: a cross-country comparative analysis applied to the PRONOUNCE trial in non-squamous non-small cell lung cancer. Adv Ther. 2015 Dec 9;32(12):1248-62. doi: 10.1007/s12325-015-0270-9
Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National Lymphocare Study. J Clin Oncol. 2015 Aug 10;33(23):2516-22.
Stull DE, McBride D, Houghton K, Finlay AY, Balp MM. Correlation between UAS7 categorical health states and DLQI score bands to assess burden of disease and response to treatment in chronic idiopathic/spontaneous patients (CIU/CSU). Poster presented at the 23rd World Congress of Dermatology; June 2015. Vancouver, Canada.
Stull DE, McBride D, Houghton K, Balp MM. Are changes in chronic urticaria symptoms and sleep experience correlated?: a post-hoc analysis from phase II trials of omalizumab in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU). Poster presented at the 23rd World Congress of Dermatology; June 2015. Vancouver, Canada.
Benson C, Chirila C, Graham J, Radder C, Zheng Q, Muser E, Woodruff K. Health resource use and cost analysis of schizophrenia patients participating in a randomized, multicenter, double-blind, relapse prevention study of paliperidone palmitate 3-month formulation. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Stull D, McBride D, Houghton K, Finlay A, Gnanasakthy A, Balp MM. Correlations between changes in urticaria activity score, dermatologic-related quality of life, and urticaria-specific quality of life: results from the Ph III trials of omalizumab in CIU/CSU patients. Poster presented at the American Academy of Dermatology 72nd Annual Meeting; March 21, 2015. Denver, CO.
Stull DE, McBride D, Houghton K, Balp MM. A positive correlation between changes in urticaria symptoms (UAS7) and dermatologic-related quality of life (DLQI) and urticaria-specific quality of life (CU-Q2oL): is it informative about the response to treatment in CSU/CIU patients? Poster presented at the Maui Derm for Dermatologists; January 26, 2015. Maui, HI. Previously presented at the Fall Clinical Dermatology Conference.
Stull D, McBride D, Houghton K, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomized, double-blind, placebo-controlled Phase III trials of omalizumab. Poster presented at the Maui Derm for Dermatologists; January 26, 2015. Maui, HI. Previously presented at the Fall Clinical Dermatology Conference.
Stull D, McBride D, Houghton K, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomized, double-blind, placebo-controlled Phase III trials of omalizumab. Poster presented at the Winter Clinical Dermatology Conference; January 16, 2015. Kaanapali, HI. Previously presented at the Fall Clinical Dermatology Conference.
Stull D, McBride D, Houghton K, Balp M-M. A positive correlation between changes in urticaria symptoms (UAS7) and dermatologic-related quality of life (DLQI) and urticaria-specific quality of life (CU-Q2oL): is it informative about the response to treatment in CSU/CIU patients? Poster presented at the Fall Clinical Dermatology Conference; October 16, 2014. Las Vegas, NV.
Stull D, McBride D, Houghton K, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomized, double-blind, placebo-controlled, Phase III trials of omalizumab. Poster presented at the Fall Clinical Dermatology Conference; October 16, 2014. Las Vegas, NV.
Stull D, McBride D, Houghton K, Finlay A, Gnanasakthy A, Balp M-M. A positive correlation between changes in urticaria symptoms (UAS7) and dermatologic-related quality of life (DLQI) and urticaria-specific quality of life (CU-Q2oL): is it informative about the response to treatment in CSU/CIU patients? Poster presented at the European Academy of Dermatology and Venereology; October 11, 2014. Amsterdam, the Netherlands. Previously presented at the Fall Clinical Dermatology Conference.
Stull D, McBride D, Houghton K, Finlay A, Gnanasakthy A, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomised, double-blind, placebo-controlled phase III trials of omalizumab. Poster presented at the European Academy of Dermatology and Venereology; October 8, 2014. Amsterdam, the Netherlands. Previously presented at the Fall Clinical Dermatology Conference.
Stull D, McBride D, Houghton K, Finlay A, Gnanasakthy A, Balp MM. Changes in urticaria symptoms, dermatologic-related quality of life, and urticaria-specific quality of life: are they telling us the same thing about response to treatment for chronic spontaneous/idiopathic urticaria (CSU/CIU)? Poster presented at the European Academy of Allergy and Clinical Immunology Congress; June 2014. Copenhagen, Denmark.
Stull D, McBride D, Houghton K, Finlay A, Balp MM. Correlation between changes in weekly disease severity score and quality of life scores in chronic spontaneous/idiopathic urticaria (CSU/CIU): are they equally informative about the response to treatment? Poster presented at the AAAAI Annual Meeting; February 28, 2014. San Diego, CA.
Wong-Sefidan I, Byrtek M, Zhou X, Friedberg JW, Flowers CR, Link BK. PET compared with CT as a prognosticator after rituximab induction therapy in follicular lymphoma: report from the National LymphoCare Study. Poster presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition; December 2013. New Orleans, LA. [abstract] Blood. 2013 Nov 15; 122(21):4245. doi: 10.1182/blood.V122.21.4245.4245
Stull DE, McBride D, Gnanasakthy A, Balp M. Correlations between changes in the urticaria activity score (UAS7) and the dermatology life quality index (DLQI) from baseline to 28 or 40 weeks: comparisons of trajectories of change in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU). Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A509.
Raspa M, Bishop E, Candrilli S, Mitra D, Sacco P, Petrillo J, Bailey D. US caregiver burden in Fragile X syndrome as a function of a health-state utility index. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A625.
Wong-Sefidan I, Byrtek M, Zhou X, Dawson K, Friedberg J, Flowers CR, Zelenetz A, Reid E. Non-clinical factors drive imaging patterns after induction therapy of follicular lymphoma (FL): report from the National LymphoCare Study (NLCS). Poster presented at the 2013 12th International Conference on Malignant Lymphoma; June 2013. Lugano, Switzerland. [abstract] Hematol Oncol. 2013 Jun 17; 31(S1):255.
Davis KL, Meyers J, Zhao Z, McCollam P, Murakami M. High-risk vascular disease in Japan: evidence on incidence and prevalence, patient characteristics, and treatment rates from a large Japanese claims database. Poster presented at the 2013 ISPOR 18th Annual International Meeting; April 23, 2013. [abstract] Value Health. 2013 Apr; 16(3):A277.
Kilpatrick RD, Gilbertson D, Brookhart MA, Polley E, Rothman KJ, Bradbury BD. Exploring large weight deletion and the ability to balance confounders when using inverse probability of treatment weighting in the presence of rare treatment decisions. Pharmacoepidemiol Drug Saf. 2013 Feb 1;22(2):111-21.
Martin P, Link BK, Byrtek M, Dawson K, Ziemiecki RM, Friedberg J. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National Lymphocare Study. Poster presented at the 54th American Society of Hematology (ASH) Annual Meeting and Exposition; December 8, 2012. Atlanta, GA. [abstract] Blood. 2012 Nov 16; 120(21):3702. doi: 10.1182/blood.V120.21.3702.3702
Davis KL, Mitra D, Yen L. Clinical characteristics, treatment patterns, and resource utilization in a real-world European population with diverticulitis. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 9, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A535-6.
Kiladjian JJ, Gisslinger H, Passamonti F, Neiderwieser D, Medelson E, Sirulnik LA, Copley-Merriman K, Zhou X. Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. Poster presented at the European School of Haematology (ESH) International Conference on Myeloproliferative Neoplasms; October 4, 2012. Previously presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO).
Christiansen CF, Pedersen L, Sorensen HT, Rothman KJ. Methods to assess seasonal effects in epidemiological studies of infectious diseases-exemplified by application to the occurrence of meningococcal disease. Clin Microbiol Infect. 2012 Oct 1;18(10):963-9.
Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki RM, Taylor M, Friedberg J. Effectiveness of first-line chemoimmunotherapy regimens for patients diagnosed with follicular lymphoma in the United States: data from the national lymphocare study. Poster presented at the 17th Congress of the European Hematology Association; June 14, 2012.
Lunt M, Glynn RJ, Rothman KJ, Avorn J, Sturmer T. Propensity score calibration in the absence of surrogacy. Am J Epidemiol. 2012 Jun 1;175(12):1294-302.
Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012 May 1;21(Suppl. 2):69-80.
Coon CD, Fehnel SE, Davis KH, Runken MC, Beach ME, Cady RK. The development of a survey to measure completeness of response to migraine therapy. Headache. 2012 Apr 1;52(4):550-72.
Sherrill B, Sherif B, Amonkar MM, Maltzman J, O'Rourke L, Johnston S. Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib. Curr Med Res Opin. 2011 Dec 1;27(12):2245-52.
Rahman MQ, Abeysinghe SS, Kelly S, Roskell NS, Shannon PR, Abdlseaed AA, Montgomery DMI. Persistence of glaucoma medical therapy in the Glasgow Glaucoma Database. Br J Ophthalmol. 2011 Jul 1;95(7):966-70.
Odom D, Barber B, Bennett L, Peeters M, Zhao Z, Kaye J, Wolf M, Wiezorek J. Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab. Int J Colorectal Dis. 2011 Feb 1;26(2):173-81.
Chirila C, Earnshaw SR, Black L, McDade CL, Roskell NS, Shannon PR, Montorsi F, Andriole GL. Economic analysis: randomized, placebo-controlled clinical trial of dutasteride in men at high risk for prostate cancer. J Cancer Sci Ther. 2011;S3(004). doi: 10.4172/1948-5956.S3-004
Amonkar MM, Sherrill B, Zhou X. A review of the impact of lapatinib on health-related quality of life of patients with newly diagnosed and refractory metastatic breast cancer. Poster presented at the 2010 Breast Cancer Symposium; October 4, 2010. National Harbor, MD.
Johannes C, Odom D, Bennett L, Foley D. The impact of menopause status on formal vs. informal care-seeking behavior in women with decreased sexual desire with associated distress. J Sex Med. 2010 May 1;7(Suppl. 3):123.
Davis KL, Edin HM, Allen JK. Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data. Mov Disord. 2010 Mar 15;25(4):474-80.
Johannes CB, Clayton AH, Odom DM, Rosen RC, Russo PA, Shifren JL, Monz BU. Distressing sexual problems in United States women revisited: prevalence after accounting for depression. J Clin Psychiatry. 2009 Dec 1;70(12):1698-706.
Sherrill B, Sherif BN, Amonkar M, Wu Y, Maltzman J, O'Rourke L, Johnston S. Quality of life and quality-adjusted survival (Q-TWIST) in patients receiving lapatinib plus letrozole as first-line therapy in hormone receptor positive, her2+ metastatic breast cancer. Poster presented at the Cancer Symposium of the American Society of Clinical Oncology; October 10, 2009.
Rosen R, Shifren J, Monz B, Odom D, Russo P, Johannes C. The predictors of sexual distress in women with low sexual desire. Presented at the Annual Meeting of the International Society for the Study of Women's Sexual Health; September 1, 2009.
Rosen RC, Shifren JL, Monz BU, Odom DM, Russo PA, Johannes CB. Correlates of sexually related personal distress in women with low sexual desire. J Sex Med. 2009 Jun 1;6(6):1549-60.
Bland AE, Calingaert B, Secord AA, Lee PS, Valea FA, Berchuck A, Soper JT, Havrilesky L. Relationship between tamoxifen use and high risk endometrial cancer histologic types. Gynecol Oncol. 2009 Jan 1;112(1):150-4.
Mladsi DM, Irish WD, Copley-Merriman K, Bhandary D. Statistical measures of treatment effects in oncology: what are we missing? Presented at the 2008 ISPOR 11th Annual European Congress; November 2008. Athens, Greece.